Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Neu monoclonal antibody 7.16.4
- Development stage
- Preclinical
- Lead developer
- University of Pennsylvania
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
anti-Neu monoclonal antibody 7.16.4 is a mouse IgG2a monoclonal antibody that targets the p185 HER2/neu (c-ErbB2) oncoprotein. It specifically recognizes the juxtamembrane/extracellular domain of rat neu and competes with 4D5 (the precursor of trastuzumab) for binding. Originally developed by Dr. Mark Greene and colleagues at the University of Pennsylvania, this antibody is widely used as a preclinical research tool to study HER2/neu-overexpressing cancers, particularly mammary carcinomas. It has been shown to inhibit tumor cell proliferation and transformation in vitro and in vivo, and is frequently utilized in combination studies with vaccines, chemotherapies, and other targeted agents to model clinical translation of HER2-targeted therapies.
- Other names
- anti-Neu mAb 7.16.4anti-c-ErbB2/c-Neu Ab-4clone 7.16.4clone7.16.4clone-7.16.4mAb 7.16.4mAb7.16.4mAb-7.16.4
02
Targets
Beyond the preview
Go deeper on anti-Neu monoclonal antibody 7.16.4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Neu monoclonal antibody 7.16.4.